StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report released on Sunday. The firm issued a sell rating on the stock.
Bio-Path Stock Performance
Shares of BPTH stock opened at $0.77 on Friday. The company’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.48. Bio-Path has a one year low of $0.61 and a one year high of $12.37.
Hedge Funds Weigh In On Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Following Congress Stock Trades
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
